Quantification of Seminal Plasma Motility Inhibitor/Semenogelin in Human Seminal Plasma
書誌事項
- 公開日
- 2003-11-12
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/j.1939-4640.2003.tb03139.x
- 公開者
- Wiley
この論文をさがす
説明
<jats:p><jats:bold>ABSTRACT: </jats:bold> Semenogelin I and II (Sg I and II) are the major components of human semen coagulum. The protein is rapidly cleaved after ejaculation by the chymotrypsin‐like protease prostate‐specific antigen (PSA), which results in the liquefaction of the semen coagulum and the progressive release of motile spermatozoa. One of the cleavage products of the protein, a 14‐kDa protein, is a sperm motility inhibitor (seminal plasma motility inhibitor [SPMI]). We developed a monoclonal antibody (mAb) that is specific to the fragment of Sgs, SPMI, and a sandwich enzyme‐linked immunosorbent assay (ELISA) system for the quantification of Sgs using this mAb. Then, we measured SPMI/Sg levels in human seminal plasma from healthy male volunteers (n = 100, aged 18–24 years). The mean level of SPMI/Sg in seminal plasma was 19 ± 13 mg/mL (range, 4–68 mg/mL). Log‐transformed SPMI/Sg levels were negatively correlated with the sperm motility (<jats:italic>r</jats:italic> = −0.229, <jats:italic>P</jats:italic> = .0220) and positively correlated with the total protein concentration (<jats:italic>r</jats:italic> = 0.793, <jats:italic>P</jats:italic> < .0001). This result supports that SPMI, one of the fragments of Sg, has its inhibitory effect on ejaculated spermatozoa in liquefied semen under physiological conditions.</jats:p>
収録刊行物
-
- Journal of Andrology
-
Journal of Andrology 24 (6), 878-884, 2003-11-12
Wiley